Eloxatin Symptom-Based Clinical Benefit Could Support Full Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Demonstration of symptom-based clinical benefit could be used to support full approval of Sanofi-Synthelabo’s second-line colorectal cancer therapy Eloxatin, FDA indicated in review documents for the Aug. 9, 2002, accelerated approval.
You may also be interested in...
Eloxatin Adjuvant Indication Could Nearly Double Sanofi’s Target Market
Sanofi-Synthelabo’s pending NDA for use of Eloxatin in the adjuvant colorectal cancer setting could roughly double the potential patient population for the oncologic.
Eloxatin Adjuvant Indication Could Nearly Double Sanofi’s Target Market
Sanofi-Synthelabo’s pending NDA for use of Eloxatin in the adjuvant colorectal cancer setting could roughly double the potential patient population for the oncologic.
Faslodex Name Confusion Not Prevented By Differences In Dosage Form - FDA
Differences in dosage form or administration routes do not always prevent confusion of similar drug names, FDA’s Division of Medication Errors & Technical Support suggests in review documents for AstraZeneca’s breast cancer drug Faslodex.